AML | Clinical

Enrollment Milestone Reached for Phase 3 Study of Devimistat in AML

April 02, 2021

The phase 3 ARMADA 2000 trial, which aims to determine the efficacy and safety of devimistat in combination with high-dose cytarabine and mitoxantrone compared to controls for older patients with relapsed or refractory acute myeloid leukemia, has crossed the enrollment of 150 participants.

FDA Approves a Revised Indication for Daunorubicin/Cytarabine for the Treatment of Pediatric AML

March 31, 2021

The FDA has revised the approval of daunorubicin and cytarabine to add 2 new indications for the treatment of newly diagnosed therapy-related acute myeloid leukemia or for AML with myelodysplasia-related changes in pediatric patients aged 1 year and older.

Gilteritinib Prolongs OS Over Chemotherapy in FLT3 + Acute Myeloid Leukemia

March 30, 2021

Gilteritinib showed improvement in overall survival in patients with relapsed or refractory FLT3 mutation-positive acute myeloid leukemia compared with chemotherapy, meeting the primary end point of the phase 3 COMMODORE confirmatory trial.

Aiming for OS Improvement in AML With Venetoclax Plus FLAG-IDA Induction/Consolidation

March 08, 2021

Curtis Lachowiez, MD, discusses the interim analysis of the phase 1b/2 study of venetoclax in combination with standard intensive acute myeloid leukemia induction plus consolidation therapy with the FLAG-IDA regimen as treatment of patients with newly diagnosed or relapsed/refractory AML

Novel T-Cell Based Immunotherapy Dosed Phase 2 Study of Patients With AML

March 03, 2021

The first patient with acute myeloid leukemia in a phase 2 trial of the MultiTAA-specific T cell, MT-401 followed stem-cell transplant has been dosed with the agent, according to a press release by Marker Therapeutics, Inc.